IP Library › Granted Patent US 7,025,961
Granted Patent B1
US 7,025,961 · App. 09/914,694 · Granted Apr 11, 2006

Anti-plasmodium composition and methods of use

Assignee: The United States of America as represented by the Department of Health and Human Services
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,025,961
App. No.
09/914,694
Granted
Apr 11, 2006
Kind
B1
Abstract

Compositions that inhibit the binding of Plasmodium falciparum to erythrocytes are provided. More particularly, antibodies specific for Plasmodium falciparum binding proteins and blocking peptides that prevent the binding of Plasmodium falciparum are included in the present invention. The methods provided utilize the antibody and peptide compositions provided herein and include methods for the diagnosis, prevention, and treatment of Plasmodium falciparum diseases such as malaria as well as methods for the detection of Plasmodium falciparum in biological samples and culture media.

Claims (8)

1. An isolated antibody, wherein the antibody specifically binds a region of a RII/F2 region of an EBA-175 protein from a Plasmodium species, wherein the region consists of a 10 amino acid sequence and wherein the amino acid sequence is shown in SEQ ID NO: 1.

2. The isolated antibody of claim 1 , wherein the P. species is Plasmodium falciparum.

3. The isolated antibody of claim 1 , wherein the antibody inhibits binding of an EBA-175 protein to a red blood cell.

4. The isolated antibody of claim 1 , wherein the antibody inhibits Plasmodium falciparum invasion into a red blood cell.

5. The isolated antibody of claim 4 , wherein the antibody inhibits Plasmodium falciparum invasion of a red blood cell in vitro.

6. The isolated antibody of claim 4 , wherein the antibody inhibits Plasmodium falciparum invasion of a red blood cell in vivo.

7. The isolated antibody of claim 1 , wherein the antibody is monoclonal.

8. A hybridoma producing the monoclonal antibody of claim 7 .

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 7, 2004
From: ENTREMED, INC.
To: HEALTH AND HUMAN SERVICES, DEPARTMENT OF, THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY,
Reel/Frame 014241/0309 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 19, 2002
From: NARUM, DAVID L.; SIM, KIM LEE
To: ENTREMED, INC.
Reel/Frame 012633/0464 →
Continuity (2)
Provisional Application 6015357500 · Sep 13, 1999
Provisional Application 6012284200 · Mar 4, 1999